UAWJ246 

UAWJ246 is a covalent reversible inhibitor of the SARS-CoV-2 main protease (Mpro), with an IC₅₀ of 0.045 μM and a Ki of 0.036 μM. UAWJ246 exhibits potent antiviral activity by inhibiting SARS-CoV-2 viral replication and shows low cytotoxicity. UAWJ246 can be used in research related to SARS-CoV-2 infection, such as studies on COVID-19^[1][2].

UAWJ246 (0.37-30 μM, 48 h) inhibits SARS-CoV-2 viral replication in Vero E6 cells in a dose-dependent manner^[1].
UAWJ246 (3 days) inhibits the viral replication of SARS-CoV-2 in Vero E6 cells with an EC₅₀ of 4.61 μM in the plaque assay^[1].
UAWJ246 (5 days) shows low cytotoxicity in multiple cell lines with CC₅₀s > 100 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

486.57

C₂₅H₃₄N₄O₆

1429218-79-0

[C@@H](C[C@H]1C(=O)NCC1)(NC([C@@H](NC(OCC2=CC=CC=C2)=O)CC(C)C)=O)C(C(NC3CC3)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Sacco MD, et al. Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M^pro and cathepsin L. Sci Adv. 2020;6(50):eabe0751. Published 2020 Dec 9.  [Content Brief]

  [2]. La Monica G, et al. Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure-Activity Relationship Insights and Evolution Perspectives. J Med Chem. 2022;65(19):12500-12534.  [Content Brief]